title: Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
abstract: The development of inhibitors to the infused factor in patients with haemophilia is a serious clinical problem. Recent evidence suggests that alongside the strong genetic contribution to inhibitor formation, there are a number of non-genetic factors--perceived by the immune system as danger signals--which promote formation of inhibitors. This study provides a comprehensive review of clinical studies relating to these factors and also presents a survey of opinion concerning their importance and clinical influence, conducted among the members of the European Haemophilia Treatment Standardisation Board (EHTSB). Taken together, this information highlights the lack of robust data concerning the influence of several non-genetic risk factors on inhibitor development, and an urgent need for prospective, well-conducted studies that adhere to recommendations made by the European Medicines Agency (EMEA) for studying inhibitors. Based on current literature, the EHTSB formulated consensus recommendations. It is desirable to minimize intensive treatment wherever possible, given the clinical situation. Prophylaxis should be offered to all children, although we still need to determine optimal dosing with respect to inhibitor development, and age for starting treatment. Vaccinations should be given subcutaneously and concomitant factor concentrate infusions avoided. According to the board, there is no evidence in the literature supporting suggestions that the type of concentrate influences inhibitor risk; but all patients should be monitored during their first exposures. Furthermore, there is no evidence to support an association between pregnancy-related issues, breast feeding and treatment-related factors (e.g. route of administration, or use of blood components) and inhibitor development.
authors.affiliation: Centre for Thrombosis and Haemostasis, Malmö University Hospital, Malmö, Sweden. Jan.astermark@med.lu.se
authors.forename: J
authors.initials: J
authors.lastname: Astermark
authors.forename: C
authors.initials: C
authors.lastname: Altisent
authors.forename: A
authors.initials: A
authors.lastname: Batorova
authors.forename: M J
authors.initials: MJ
authors.lastname: Diniz
authors.forename: A
authors.initials: A
authors.lastname: Gringeri
authors.forename: P A
authors.initials: PA
authors.lastname: Holme
authors.forename: A
authors.initials: A
authors.lastname: Karafoulidou
authors.forename: M F
authors.initials: MF
authors.lastname: Lopez-Fernández
authors.forename: B M
authors.initials: BM
authors.lastname: Reipert
authors.forename: A
authors.initials: A
authors.lastname: Rocino
authors.forename: M
authors.initials: M
authors.lastname: Schiavoni
authors.forename: M
authors.initials: M
authors.lastname: von Depka
authors.forename: J
authors.initials: J
authors.lastname: Windyga
authors.forename: K
authors.initials: K
authors.lastname: Fijnvandraat
mesh_terms: D000367:Age Factors; D019774:Blood Coagulation Factor Inhibitors; D001942:Breast Feeding; D036861:Delivery, Obstetric; D005169:Factor VIII / Q000008:administration & dosage*; D005260:Female; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology*; D006801:Humans; D008297:Male; D011247:Pregnancy; D012307:Risk Factors
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII